Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
25 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Nevro Enters Into Cooperation Agreement With Engaged Capital
21 Feb 24
8-K
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
21 Feb 24
EFFECT
Notice of effectiveness
11 Jan 24
424B3
Prospectus supplement
10 Jan 24
8-K
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
9 Jan 24
CORRESP
Correspondence with SEC
8 Jan 24
UPLOAD
Letter from SEC
4 Jan 24
S-3
Shelf registration
28 Dec 23
8-K
Nevro Announces Acquisition of Vyrsa™ Technologies
1 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
1 Nov 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
1 Aug 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Departure of Directors or Certain Officers
5 Jun 23
8-K
Departure of Directors or Certain Officers
30 May 23
SD
Conflict minerals disclosure
23 May 23
10-Q
2023 Q1
Quarterly report
26 Apr 23
8-K
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
26 Apr 23
S-8
Registration of securities for employees
21 Apr 23
8-K
Results of Operations and Financial Condition
19 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
S-8
Registration of securities for employees
21 Feb 23
10-K
2022 FY
Annual report
21 Feb 23
8-K
Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results
16 Feb 23
8-K
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
9 Jan 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
2 Nov 22
8-K
Departure of Directors or Certain Officers
9 Sep 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
3 Aug 22
8-K
Other Events
1 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
31 May 22
SD
Conflict minerals disclosure
23 May 22
Latest ownership filings
4
Kevin R Thornal
26 Apr 24
4
D KEITH GROSSMAN
15 Apr 24
4
Kashif Rashid
8 Apr 24
4
Sridhar Kosaraju
2 Apr 24
4
MICHAEL F DEMANE
2 Apr 24
4
ELIZABETH H WEATHERMAN
2 Apr 24
4
Frank M Fischer
2 Apr 24
4
D KEITH GROSSMAN
13 Mar 24
4
Kevin R Thornal
11 Mar 24
4
Kashif Rashid
11 Mar 24
4
GREG SILLER
11 Mar 24
4
Roderick H. MacLeod
11 Mar 24
4
Richard B. Carter
11 Mar 24
4
D KEITH GROSSMAN
6 Mar 24
4
Roderick H. MacLeod
6 Mar 24
4
Richard B. Carter
6 Mar 24
4
Kashif Rashid
6 Mar 24
4
Richard B. Carter
5 Mar 24
4
D KEITH GROSSMAN
5 Mar 24
4
Roderick H. MacLeod
5 Mar 24
4
Kashif Rashid
5 Mar 24
4
Roderick H. MacLeod
1 Mar 24
4
Kashif Rashid
1 Mar 24
4
Kirt P Karros
22 Feb 24
3
Kirt P Karros
22 Feb 24
SC 13D/A
Engaged Capital LLC
21 Feb 24
SC 13G
ALGER ASSOCIATES INC
14 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
ArrowMark Colorado Holdings LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
4
Kashif Rashid
8 Jan 24
4
Sridhar Kosaraju
3 Jan 24
4
Frank M Fischer
3 Jan 24
4
ELIZABETH H WEATHERMAN
3 Jan 24
4
MICHAEL F DEMANE
3 Jan 24
SC 13D
Engaged Capital LLC
11 Dec 23
4
Richard B. Carter
5 Dec 23
4
D KEITH GROSSMAN
5 Dec 23
4
Kashif Rashid
30 Nov 23